REGISTER HERE.

In recent years, immune checkpoint inhibitors have demonstrated superior benefits in a spectrum of GI malignancies, including colorectal, esophageal, and gastric cancers. In this educational activity, experts will present a MasterClass featuring in-depth analysis of the latest evidence on the present and future use of checkpoint inhibitors in the management of GI cancers, along with practical guidance on incorporating these agents into clinical practice.

AGENDA

Welcome and Introduction
MasterClass 1 - Integrating the Pivotal Data Into Practice: The Clinical Experience With Immune Checkpoint Inhibitors in Colorectal Cancer

• Practicum 1
  Weaving Clinical Data Into the Colorectal CRC Treatment Algorithm

MasterClass 2 - Redefining the Treatment Algorithm With the Advent of Immunotherapy in Advanced Gastric, GEJ, and Esophageal Cancers
MasterClass 3 - Progress With Immunotherapy in Earlier Disease Settings

• Practicum 2
  Applying Data in the Clinic for Patients With Gastroesophageal Cancer

Audience Q&A
Key Takeaways and Conclusions

TARGET AUDIENCE

This activity has been designed to meet the educational needs of medical and gastrointestinal oncologists and other clinicians involved in the management of gastrointestinal cancers.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

• Summarize the rationale for use of checkpoint inhibitors, including when testing for PD-L1, MMR/MSI status, and other predictors of response is needed, across the spectrum of GI cancers
• Appraise the latest safety and efficacy evidence on available dual and single agent checkpoint inhibition strategies for patients with advanced GI cancers, including gastric, esophageal, GEJ, and colorectal cancers
• Review emerging data regarding the use of checkpoint inhibitors in combination regimens and in early treatment settings, including first-line and perioperative settings, for patients with GI cancers
• Develop safe and effective treatment plans incorporating immune checkpoint inhibitors, including enrollment within clinical trials, for eligible patients with advanced and earlier-stage GI cancers

ACCREDITATION

This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.